Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025

Page 10 of 14

5. INmune Bio Inc (NASDAQ:INMB)

Number of Hedge Fund Holders In Q3 2024: 8

INmune Bio Inc (NASDAQ:INMB) is a clinical-stage biotech company.

The stock is up notably so far in 2025 due to its Alzheimer’s disease trial progress. Its Phase 2 AD02 trial completed enrollment in November 2024 with top-line cognitive data expected in Q2 2025.

Early biomarker data showed reductions in ptau-217 and neurofilament light chain. As such, there is potential that this can modify the disease.

In addition, INmune Bio fully repaid its Silicon Valley Bank term loan in December 2024. This eliminated the company’s debt and reduced its cash burn.

The consensus price target of $20.75 implies 105.96% upside.

INMB stock is up 104.82% year-to-date.

Page 10 of 14